SOUTH SAN FRANCISCO, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended September 30, 2013 and to provide a general business overview on Tuesday, November 5, 2013 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Conference Call Details To access the live conference call, please dial (866) 515-2912 from the U.S. and Canada, or +1(617) 399-5126 internationally, and use the passcode 80397477. Please dial in 10 minutes prior to the start of the call. To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's website at http://investors.portola.com. Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. A replay of the webcast will be available on the Company's website for 30 days following the live event. About Portola Pharmaceuticals, Inc. Portola Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. Portola's wholly-owned lead compound, betrixaban, is a novel, oral, once-daily Factor Xa inhibitor in Phase 3 development for extended-duration prophylaxis of a form of thrombosis known as venous thromboembolism (VTE) in acute medically ill patients. Currently, there is no anticoagulant approved for extended-duration VTE prophylaxis in this population. Portola's second lead development candidate, andexanet alfa (PRT4445*), has the potential to be the first universal antidote to reverse the effects of Factor Xa inhibitors in patients who suffer an uncontrolled bleeding episode or who require emergency surgery. Portola retains full, worldwide commercial rights to andexanet alfa. Portola's third product candidate, PRT2070, is an orally available kinase inhibitor that uniquely inhibits two validated tumor proliferation pathways -- spleen tyrosine kinase (Syk) and janus kinase (JAK). It is currently being studied in patients with genetically-defined hematologic cancers, as well as for patients who have failed therapy due to relapse or acquired mutations. Portola's fourth program is partnered with Biogen Idec and is focused on the development of PRT2607, a selective Syk inhibitor. For more information, visit www.portola.com. *PRT4445 has a proposed International Nonproprietary Name (pINN) of andexanet alfa.
CONTACT: Investor Contact: Alexandra Santos Portola Pharmaceuticals firstname.lastname@example.org 650.246.7239 Media Contact: Joey Fleury BrewLife email@example.com 415.946.1090